Payment overview · 2025
General Payments
$30,998.91
82 reported records · 28 companies
Healthcare provider profile · identity verified
Eric Benjamin Trestman, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · HUMBLE, TX · NPI 1639412018
Verified facts
What the public records show
CMS Open Payments records show Eric Benjamin Trestman, M.D. received $30,998.91 in general payments during 2025 across 82 reported records.
Boston Scientific Corporation accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16,393.64 | 52.9% | 21 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $5,225.88 | 16.9% | 14 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $5,000.00 | 16.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $2,593.73 | 8.4% | 3 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $349.87 | 1.1% | 7 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $238.26 | 0.8% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $204.74 | 0.7% | 3 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $164.79 | 0.5% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$132.31 | 0.4% | 1 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $116.14 | 0.4% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $66.21 | 0.2% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $60.46 | 0.2% | 3 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $56.67 | 0.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $41.58 | 0.1% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $41.21 | 0.1% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $37.26 | 0.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $36.55 | 0.1% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $30.52 | 0.1% | 1 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $27.74 | 0.1% | 1 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.06 | 0.1% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $26.64 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $24.59 | 0.1% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $22.31 | 0.1% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $21.27 | 0.1% | 1 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $20.80 | 0.1% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $19.25 | 0.1% | 1 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $14.47 | 0.1% | 1 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $4.96 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,700.00 | 8 |
| Consulting Fee | $5,000.00 | 1 |
| Long term medical supply or device loan | $5,000.00 | 1 |
| Food and Beverage | $2,796.41 | 71 |
| Honoraria | $2,502.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $8,000.00 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $5,152.06 | 12 | 2025 |
Source payment records
|
|||||
| VENOUS WALLSTENT Normalized: venous wallstent |
Device | Boston Scientific Corporation | $5,039.29 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $2,750.00 | 2 | 2025 |
Source payment records
|
|||||
| US EQ Undivided Normalized: us eq undivided |
Device | Philips North America LLC | $2,502.50 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $429.47 | 5 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $252.21 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $204.74 | 3 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $179.39 | 2 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $132.31 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $119.64 | 6 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $113.43 | 3 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $97.66 | 4 | 2025 |
Source payment records
|
|||||
| Duo Hybrid Normalized: duo hybrid |
Device | Philips North America LLC | $91.23 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $73.82 | 2 | 2025 |
Source payment records
|
|||||
| HOTSHOT CONTROLLER Normalized: hotshot controller |
Device | Imperative Care, Inc | $66.21 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $60.46 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $60.46 | 3 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $58.87 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $56.67 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $55.24 | 1 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $51.36 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $41.58 | 3 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $41.21 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $37.26 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $36.55 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $30.52 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Pharmaceuticals, Inc. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 170 | 63 |
| Xarelto | Rivaroxaban | 82 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,998.91 · 82 records | Boston Scientific Corporation | ALPHAVAC, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Attruby, Barostim Neo System, Bashir Endovascular Catheter, BioMimics 3D Vascular Stent System, CGuard Prime Carotid Stent System, CLOT MANAGEMENT, COOK, Duo Hybrid, EVKEEZA, EkoSonic, FFRct, Flexitouch Plus, GORE VIABAHN VBX Balloon Expandable Endo, General - Therapies, General - Vascular Intervention, HOTSHOT CONTROLLER, Kerecis GraftGuide, Kerecis SurgiClose, Nimbl, PICO 7, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, Ranger, Restrata Wound Matrix, RotarexS 6 F x 135 cm, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREO ABDOMINAL STENT-GRAFT SYSTEM, US EQ Undivided, VALIANT CAPTIVIA, VENOUS WALLSTENT, Varithena Administration Pack, Venclose Maven Catheter, ZENITH SPIRAL-Z | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error